Phase I Study of Single Agent Perifosine for Recurrent Pediatric Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 03 Aug 2017
At a glance
- Drugs Perifosine (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 31 Jul 2017 Planned number of patients changed from 36 to 38.
- 31 Jul 2017 Status changed from active, no longer recruiting to completed.
- 10 Jun 2017 Biomarkers information updated